Pulmonary and intestinal fibrosis share a common TGF-β-driven mechanism. Our lung and intestinal organoid models capture it for antifibrotic drug discovery.
Our team has received your request and will get back to you shortly with tailored workflows and relevant case studies for your ADC efficacy and toxicity evaluation needs.
If you do not receive our confirmation email, kindly check your spam or junk folder.
